BLA 125327 · Btg International INC
Voraxaze
Glucarpidase · Injection · Carboxypeptidase
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Aug 13, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Jan 17, 2012
Approved uses
1
Original approval plus efficacy supplements
Registered trials
32
1 Phase 3, 6 recruiting
FAERS reports
363
260 serious, 71 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 27, 2024.
VORAXAZE is indicated to reduce toxic plasma methotrexate concentration (greater than 1 micromole per liter) in adult and pediatric patients with delayed methotrexate clearance (plasma methotrexate concentrations greater than 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) due to impaired renal function. Limitations of Use: VORAXAZE is not recommended for use in patients who exhibit the expected clearance and expected plasma methotrexate concentration. Reducing plasma methotrexate concentration in these patients may result in subtherapeutic exposure to methotrexate [see Clinical Studies ( 14 )] . VORAXAZE is a carboxypeptidase indicated to reduce toxic plasma methotrexate concentration (greater than 1 micromole per liter) in adult and pediatric patients with delayed methotrexate clearance (plasma methotrexate concentrations greater than 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) due to impaired renal function. ( 1 ) Limitations of Use: VORAXAZE is not recommended for use in patients who exhibit the expected clearance and expected plasma methotrexate concentration. Reducing plasma methotrexate concentration in these patients may result in subtherapeutic exposure to methotrexate. ( 1 )
Mechanism: Glucarpidase is a recombinant bacterial enzyme that hydrolyzes the carboxyl- terminal glutamate residue from folic acid and classical antifolates such as methotrexate. Glucarpidase converts methotrexate to its inactive metabolites 4-deoxy-4-amino-N 10 - methylpteroic acid (DAMPA) and glutamate. VORAXAZE provides an alternate non-renal pathway for methotrexate elimination in patients with renal dysfunction during high-dose methotrexate treatment.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 17, 2012 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewLetter
1 products under this application
- VORAXAZE · GLUCARPIDASE 1000 UNITS PER VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Glucarpidase" as an intervention, any sponsor and status, largest first.
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT06632977 · 474 participants (planned) · Start Feb 6, 2025 · Primary completion Apr 11, 2030
Drug: Valemetostat Tosylate; Carboplatin and 4 more · For: Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
Sites: Birmingham, Alabama; Tucson, Arizona; Chico, California · 108 sites in all
- Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean StudyPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT05053152 · 194 participants (planned) · Start Apr 20, 2022 · Primary completion Feb 1, 2029
Drug: Placebo Administration; Relugolix · For: Oligometastatic Prostate Carcinoma; Prostate Adenocarcinoma; Prostate Ductal Adenocarcinoma and 2 more
Sites: Phoenix, Arizona; Berkeley, California; Beverly Hills, California · 245 sites in all
University of WashingtonAcademic, hospital or other
NCT04175431 · 100 participants (planned) · Start Sep 30, 2020 · Primary completion Jul 1, 2032
Drug: Abiraterone Acetate; Prednisone and 1 more · For: Prostate Adenocarcinoma
Sites: Pittsburgh, Pennsylvania; Seattle, Washington
Jonsson Comprehensive Cancer CenterAcademic, hospital or other
NCT06216249 · 90 participants (planned) · Start Aug 1, 2024 · Primary completion Dec 31, 2027
Drug: Lutetium Lu 177 Vipivotide Tetraxetan · For: Prostate Carcinoma; Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Sites: Los Angeles, California
- Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate CancerStatus unknown
University of Kansas Medical CenterAcademic, hospital or other
NCT06129851 · 90 participants (planned) · Start Nov 20, 2023 · Primary completion Oct 23, 2025
Drug: Relugolix · For: Stage IIC Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8
Sites: Kansas City, Kansas
- Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate CancerNot yet recruiting
Emory UniversityAcademic, hospital or other
NCT07860554 · 88 participants (planned) · Start Nov 2, 2026 · Primary completion Dec 31, 2027
Drug: Lutetium Lu 177 Vipivotide Tetraxetan · For: Metastatic Castration-Resistant Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
Sites: Atlanta, Georgia
University of WashingtonAcademic, hospital or other
NCT07698535 · 64 participants (planned) · Start Nov 15, 2026 · Primary completion Jul 5, 2029
Drug: Lutetium Lu 177 Vipivotide Tetraxetan; Docetaxel · For: Metastatic Castration-Resistant Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
Sites: Seattle, Washington
- LTA Pilot Study of Glucarpidase in Patients With Central Nervous System LymphomaActive, not recruiting
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT03684980 · 58 participants · Start Nov 14, 2018 · Primary completion Nov 2027
Drug: Methotrexate; Rituximab and 2 more · For: Central Nervous System Lymphoma
Sites: Birmingham, Alabama; Boston, Massachusetts; Basking Ridge, New Jersey · 11 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use92
- underdose62
- laboratory test interference58
- acute kidney injury36
- blood creatinine increased34
- toxicity to various agents34
- drug effect incomplete33
- rebound effect33
- drug ineffective31
- death27
- renal failure25
- mucosal inflammation23
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 9 |
| 2014 | 8 |
| 2015 | 17 |
| 2016 | 25 |
| 2017 | 16 |
| 2018 | 56 |
| 2019 | 18 |
| 2020 | 42 |
| 2021 | 41 |
| 2022 | 18 |
| 2023 | 33 |
| 2024 | 21 |
| 2025 | 23 |
| 2026 | 32 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase 2 study of glucarpidase in patients with delayed methotrexate elimination after high-dose methotrexate therapy.
Ogawa A, Kawamoto H, Hara J, et al. · Cancer Chemother Pharmacol 2024 · Clinical Trial, Phase II, Multicenter Study
- Low-Dose Planned Glucarpidase Allows Safe Outpatient High-Dose Methotrexate Treatment for CNS Lymphoma.
Schaff LR, Carlow D, Schofield R, et al. · JCO Oncol Pract 2024 · Clinical Trial, Phase I, Research Support, N.I.H., Extramural
- [Phase II study of glucarpidase in Japanese patients with delayed methotrexate clearance after high-dose methotrexate therapy].
Okada K, Ogawa C, Kayatani R, et al. · Rinsho Ketsueki 2025 · Clinical Trial, Phase II, Multicenter Study
- Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study.
Schaff LR, Lobbous M, Carlow D, et al. · BMC Cancer 2022 · Clinical Trial, Phase I, Multicenter Study
- Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.
Ghannoum M, Roberts DM, Goldfarb DS, et al. · Clin J Am Soc Nephrol 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Pharmacokinetics and Pharmacodynamics of Glucarpidase Rescue Treatment After High-dose Methotrexate Therapy Based on Modeling and Simulation.
Kimura T, Fukaya Y, Hamada Y, et al. · Anticancer Res 2023 · Clinical Trial, Phase II
Sponsor: Btg International INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.